Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3 -ITD Mutated Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3 -ITD Mutated Acute Myeloid Leukemia

Published:2018-08-31 Issue:9 Volume:93 Page:1136-1141
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Ohanian Maro¹,Garcia-Manero Guillermo¹,Levis Mark²,Jabbour Elias¹,Daver Naval¹,Borthakur Gautam¹,Kadia Tapan¹,Pierce Sherry¹,Burger Jan¹,Richie Mary Ann¹,Patel Keyur¹,Andreeff Michael¹,Estrov Zeev¹,Cortes Jorge¹,Kantarjian Hagop¹,Ravandi Farhad¹

Affiliation:

1. Department of Leukemia; University of Texas MD Anderson Cancer Center; Houston Texas

2. Division of Hematological Malignancies; Johns Hopkins Sidney Kimmel Cancer Center; Baltimore Maryland

Funder

Onyx/Bayer and Celgene

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25198/fullpdf

Reference22 articles.

1. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation;Ravandi;Blood,2013

2. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors;Levis;Blood,2006

3. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo;Sato;Blood,2011

4. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia;Cheson;J Clin Oncol,1990

5. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study;Whitman;Blood,2010

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives;European Journal of Medicinal Chemistry;2024-11

2. Approaches to anticancer therapy based on modulation of DNA methylation;Siberian journal of oncology;2024-09-09

3. Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments;Current Opinion in Oncology;2024-08-27

4. The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia;Expert Review of Hematology;2024-05-20

5. Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors;Current Treatment Options in Oncology;2024-05-02